{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-014359","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2025-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.826043+00:00","generated_at":"2026-05-26T20:57:23.806725+00:00","sec_items":["8.01","2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Citius Pharma Q1 2025 net loss $10.3M; prepares LYMPHIR launch H1 2025","bullets":["Net loss of $10.3M ($1.30 per share) vs. $9.2M ($1.45) in Q1 2024; cash $1.1M as of Dec 31, 2024.","G&A expenses rose to $5.4M on pre-launch LYMPHIR activities; R&D fell to $2.1M as trials completed.","LYMPHIR received permanent J-code (J9161) effective April 1, 2025; launch expected in first half 2025.","Citius Oncology engaged Jefferies to evaluate strategic alternatives; raised $6.5M in equity placements.","Nasdaq compliance regained after 1-for-25 reverse stock split in November 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-014359","json":"https://secwatch.observer/filing/0001213900-25-014359.json","markdown":"https://secwatch.observer/filing/0001213900-25-014359.md","text":"https://secwatch.observer/filing/0001213900-25-014359.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025014359/0001213900-25-014359-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025014359/ea0231245-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T20:57:23.806725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}